Abstract
Abnormally phosphorylated tau, an indicator of Alzheimer’s disease, accumulates in the first decades of life in the locus coeruleus (LC), the brain’s main noradrenaline supply. However, technical challenges in reliable in-vivo assessments have impeded research into the role of the LC in Alzheimer’s disease.
We studied participants with or known to be at-risk for mutations in genes causing autosomal-dominant Alzheimer’s disease (ADAD) of early onset, providing a unique window into the pathogenesis of Alzheimer’s largely disentangled from age-related factors. Using high- resolution MRI and tau PET, we revealed lower rostral LC integrity in symptomatic participants. LC integrity was associated with individual differences in tau burden and memory decline. Post- mortem analyses in a separate set of carriers of the same mutation confirmed substantial neuronal loss in the LC.
Our findings link LC degeneration to tau burden and memory in Alzheimer’s and highlight a role of the noradrenergic system in this neurodegenerative disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MJD is recipient of a stipend from the GA. Lienert-Foundation and was supported by a stipend from the Davis School of Gerontology, University of Southern California. MM's work was supported by an Alexander von Humboldt fellowship, a Max Planck Sabbatical Award, and by National Institutes of Health (NIH) grant R01AG025340. MW-B received support from the German Research Foundation (DFG, WE 4269/5-1) and the Jacobs Foundation (Early Career Research Fellowship 2017-2019). BLK was supported by a NIH grant F32AG057162. YS was supported by NIH grants RF1AG064584 and RF1AG056573. JMR was supported by NIH grants U01AG051218, R01AG062007, and P30AG066530
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval by the University of Southern California (PI: Prof. John Ringman)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Revised manuscript. Figure 4 revised; Figure 8 added; Table 3 added; Supplementary information added
Data Availability
The here described LC meta mask as well as pontine reference mask is available for download on an Open Science Framework repository (osf.io/sf2ky/). All sources for previously published masks are listed in Table 1. For access to raw imaging and clinical data, please refer to the HCP (http://nda.nih.gov/ccf).
